Cue Biopharma (NASDAQ:CUE) Receives “Outperform” Rating from Oppenheimer

by · The Cerbat Gem

Oppenheimer reissued their outperform rating on shares of Cue Biopharma (NASDAQ:CUE – Free Report) in a report released on Tuesday morning, Benzinga reports. Oppenheimer currently has a $10.00 target price on the stock.

CUE has been the topic of a number of other reports. Piper Sandler reissued an overweight rating and set a $8.00 price target on shares of Cue Biopharma in a research report on Wednesday, April 3rd. Jefferies Financial Group began coverage on shares of Cue Biopharma in a research report on Wednesday, March 13th. They set a buy rating and a $6.00 price target on the stock.

Get Our Latest Analysis on CUE

Cue Biopharma Stock Down 0.8 %

CUE opened at $1.76 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.01 and a quick ratio of 3.01. The company’s 50-day moving average is $2.07 and its 200 day moving average is $2.34. Cue Biopharma has a fifty-two week low of $1.66 and a fifty-two week high of $5.12. The firm has a market capitalization of $85.61 million, a P/E ratio of -1.60 and a beta of 2.02.

Institutional Trading of Cue Biopharma

Several hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its position in Cue Biopharma by 0.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 457,667 shares of the company’s stock worth $1,305,000 after acquiring an additional 3,495 shares during the period. Goldman Sachs Group Inc. raised its position in Cue Biopharma by 26.5% in the second quarter. Goldman Sachs Group Inc. now owns 17,607 shares of the company’s stock worth $64,000 after acquiring an additional 3,683 shares during the period. Engineers Gate Manager LP raised its position in Cue Biopharma by 17.7% in the first quarter. Engineers Gate Manager LP now owns 25,589 shares of the company’s stock worth $125,000 after acquiring an additional 3,849 shares during the period. Swiss National Bank raised its position in Cue Biopharma by 8.2% in the first quarter. Swiss National Bank now owns 67,600 shares of the company’s stock worth $330,000 after acquiring an additional 5,100 shares during the period. Finally, Barclays PLC raised its position in Cue Biopharma by 114.7% in the second quarter. Barclays PLC now owns 12,946 shares of the company’s stock worth $48,000 after acquiring an additional 6,917 shares during the period. Institutional investors own 35.04% of the company’s stock.

About Cue Biopharma

(Get Free Report)

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.

Featured Stories